Antipsychotic Drugs Market Report 2026

The antipsychotic drugs market size has grown strongly in recent years. It will grow from $21.25 billion in 2025 to $23.23 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to introduction of first-generation antipsychotics, growing awareness of mental health disorders, expansion of hospital and clinical infrastructure, rising prevalence of schizophrenia and bipolar disorder, increased r&d investments in neuropsychiatric drugs.

The antipsychotic drugs market size is expected to see strong growth in the next few years. It will grow to $33.26 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to advancements in atypical and partial dopamine agonists, adoption of precision medicine approaches, integration of ai in mental health diagnostics, expansion of online pharmacy distribution, increasing focus on long-acting injectable formulations. Major trends in the forecast period include personalized antipsychotic therapy, rising geriatric population, increasing prevalence of schizophrenia and bipolar disorder, telepsychiatry and digital mental health platforms, development of long-acting injectable antipsychotics.

The rising prevalence of mental disorders is anticipated to boost the antipsychotic drug market in the future. Mental disorders, also referred to as mental illnesses, are conditions that influence a person's thinking, behavior, mood, and overall mental health. Cases of mental disorders can be influenced by factors such as stress levels, societal pressures, genetic factors, biochemical imbalances, neurodevelopmental issues, and physical health problems. Antipsychotic drugs manage mental disorders by modulating neurotransmitter activity, mainly dopamine and serotonin, to alleviate psychotic symptoms, stabilize mood, and enhance cognitive and emotional functions. For instance, in November 2023, a survey by the Substance Abuse and Mental Health Services Administration (SAMHSA), a U.S. government agency focused on public health, revealed that about 6% of adults aged 18 or older - around 15.4 million people - had experienced serious mental illness (SMI). Moreover, in September 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that the number of people with dementia in Australia is projected to more than double, from roughly 411,100 in 2023 to 849,300 by 2058, impacting about 315,500 men and 533,800 women. Thus, the increasing incidence of mental disorders is propelling the antipsychotic drug market.

Major companies in the antipsychotic drug market are prioritizing the development of innovative medical products, like subcutaneous atypical antipsychotic injections, which provide better patient adherence and superior effectiveness over conventional oral drugs. These subcutaneous atypical antipsychotic injections are psychiatric medications administered beneath the skin to manage mental disorders, sustain consistent blood concentrations, and enhance symptom management. For example, in April 2023, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical firm, and MedinCell SA, a France-based producer of biologics and pharmaceutical preparations, introduced the FDA-approved UZEDY. This extended-release injectable version of risperidone functions as a long-acting subcutaneous injection with dosing options every one or two months. UZEDY employs MedinCell's proprietary SteadyTeq technology to deliver a consistent medication release, achieving therapeutic levels in 6-24 hours post-injection. Clinical trials showed UZEDY reduced schizophrenia relapse risk by up to 80% versus placebo. It targets adherence challenges typical of oral antipsychotics, which frequently result in relapse.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics Inc. for $14 billion. The acquisition aims to significantly enhance Bristol Myers Squibb's neuroscience portfolio by integrating Karuna's innovative antipsychotic treatment, KarXT. Additionally, the deal provides access to Karuna's early-stage and preclinical pipeline, which may further contribute to the company's long-term growth and diversification in neuroscience. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company that develops treatments for psychiatric and neurological conditions.

Major companies operating in the antipsychotic drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck And Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Aurobindo Pharma Ltd., Cipla Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Apotex Inc., Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Alkermes plc.

North America was the largest region in the antipsychotic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipsychotic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antipsychotic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the antipsychotic drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and formulation components, particularly affecting first-generation and second-generation antipsychotic segments. Regions such as North America and Europe, which rely on imports from Asia-Pacific manufacturing hubs like India and China, are most impacted by higher costs and supply chain delays. While tariffs pose challenges for pricing and availability, they also encourage local manufacturing investments and development of cost-optimized formulations, potentially strengthening regional production capabilities over time.

The antipsychotic drugs market research report is one of a series of new reports that provides antipsychotic drugs market statistics, including antipsychotic drugs industry global market size, regional shares, competitors with a antipsychotic drugs market share, detailed antipsychotic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the antipsychotic drugs industry. This antipsychotic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antipsychotic medications form a group of drugs mainly employed to control and alleviate symptoms of psychosis, such as delusions, hallucinations, paranoia, and disorganized thinking. Psychosis often occurs in mental health disorders like schizophrenia, bipolar disorder, and severe depression. These drugs are occasionally known as neuroleptics or major tranquilizers.

Antipsychotic drugs fall into three main therapeutic classes: first-generation, second-generation, and third-generation. First-generation agents, the earliest ones developed, primarily block dopamine receptors in the brain to alleviate hallucinations and delusions. They treat conditions like schizophrenia, bipolar disorder, unipolar depression, dementia, and more, and are available through channels such as hospital pharmacies, retail drug stores, and online pharmacies.

The antipsychotic drugs market consists of sales of long-acting injectables, depot injections, and atypical antipsychotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.